Senior Director of Corporate and Business Development, Regulus Therapeutics
Mr. Turner Jenkins has over a decade of broad -based experience in corporate development, venture capital, and strategic planning. Mr. Jenkins is currently the Senior Director of Corporate and Business Development for Regulus Therapeutics and is responsible for in-licensing, out-licensing, partnerships, and research collaborations. Regulus is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases.
Prior to Regulus, Mr. Jenkins was the Senior Director of Corporate Development for Otonomy where he managed in-licensing and developed the ex-US commercial strategy for Otonomy’s pipeline of products. Turner joined Pappas Ventures in 2008 and was primarily responsible for evaluating investment opportunities, performing due diligence and monitoring portfolio positions.
Previous to Pappas Ventures, he performed supply chain risk assessment, business case analysis, and strategic planning as a consultant to Amylin Pharmaceuticals, and he also has experience in financial modeling and developing go-to-market strategies for multiple biotech startups. Mr. Jenkins previously worked as a polymer chemist for MediVas, LLC, for which he developed bioabsorbable amino acid-based polymers used for controlled drug delivery applications. He is a co-author of an American Chemical Society book chapter and an inventor on two patent applications. Mr. Jenkins completed studies at UCLA (BS in Chemical Engineering with emphasis in Biomedical studies) and UC San Diego Rady School of Management (MBA).